283 related articles for article (PubMed ID: 15255163)
1. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Saijo N; Horiike A
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan therapy for small-cell lung cancer.
Sandler A
Oncology (Williston Park); 2002 Apr; 16(4):419-25, 428, 433; discussion 433-4, 437-8. PubMed ID: 12017533
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan in small-cell lung cancer--Japanese trials.
Fukuoka M; Masuda N; Kudoh S; Negoro S
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):57-62. PubMed ID: 10981292
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan in advanced lung cancer: focus on North American trials.
Langer CJ
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164
[TBL] [Abstract][Full Text] [Related]
5. Role of topoisomerase I inhibitors in small-cell lung cancer.
Fukuoka M
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
10. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Kudoh S; Nakamura S; Nakano T; Komuta K; Isobe T; Katakami N; Fukuda Y; Takada Y; Takada M; Fukuoka M; Ariyoshi Y
Lung Cancer; 2005 Aug; 49(2):263-9. PubMed ID: 16022921
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
15. Small-cell lung cancer: current therapy and novel agents.
Horiike A; Saijo N
Oncology (Williston Park); 2005 Jan; 19(1):47-52; discussion 52, 54-8. PubMed ID: 15743151
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
17. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
19. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Zatloukal P; Cardenal F; Szczesna A; Gorbunova V; Moiseyenko V; Zhang X; Cisar L; Soria JC; Domine M; Thomas M
Ann Oncol; 2010 Sep; 21(9):1810-1816. PubMed ID: 20231298
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
Jeong HC; Lee SY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
Lung Cancer; 2006 Sep; 53(3):361-6. PubMed ID: 16846662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]